Dermatitis News and Research

Latest Dermatitis News and Research

Provectus announces data from Phase 2 PV-10 metastatic melanoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting.

11 Nov 2011

Enrollment complete in Anacor's first of two tavaborole Phase 3 trials for onychomycosis

Anacor Pharmaceuticals announced today that it has completed enrollment in the first of two Phase 3 trials of tavaborole (formerly known as AN2690), a topical anti-fungal product candidate for the treatment of onychomycosis.

9 Nov 2011

KYTHERA presents long-term results from ATX-101 Phase 2 study at ASDS 2011

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, presented results from a long-term follow up study assessing persistence of efficacy and post-treatment safety of ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.

7 Nov 2011

Study evaluates availability of information about cosmetic ingredients for celiac patients

The lack of readily available information about cosmetic ingredients may cause patients with celiac disease who use lip, facial or body products to unknowingly expose themselves to gluten—an ingredient they need to avoid, according to the results of a new study unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

Thanksgiving Day tips for people with food allergies

Thanksgiving is about family, food and travel. And for the millions of Americans with allergies or asthma, it's about navigating a minefield of triggers, from the pumpkin pie to the dusty guest bedroom. "A number of holiday-related triggers can make people sneeze, wheeze or, in the case of food allergies, have a more serious reaction," said allergist Dr. Myron Zitt, past president of the Allergy, Asthma and Immunology (ACAAI). "But by planning ahead, the day can go smoothly for people with allergies or asthma."

29 Oct 2011

Lifestyle factors and nutritional patterns reduce early causes of childhood allergy

Today, about one in four European children suffer from allergy, which makes this disease the non-infectious epidemic of the 21st century. Evidence suggests that lifestyle factors and nutritional patterns, such as breastfeeding, help to reduce the early symptoms of allergy.

15 Oct 2011

UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs

Anacor Pharmaceuticals announced today that the University of California San Francisco (UCSF) has been awarded $718,136 in funding from the National Institutes of Health (NIH) to discover and optimize novel oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals. The NIH grant provides support for the period beginning September 30, 2011 and ending September 29, 2012.

12 Oct 2011

Creabilis receives $20 million in Series B funding

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures.

4 Oct 2011

Six sneaky triggers of allergies and asthma

Halloween can be a frightful time for parents of kids with allergies and asthma. Nut-filled candy isn't the only bogeyman that can ruin the fun. Allergy and asthma triggers can hide in other, unexpected places, too, from dusty costumes to leering jack-o-lanterns.

30 Sep 2011

Invida, Sinclair IS launch two dermatology products in seven Asia-Pacific markets

Sinclair IS Pharma Plc, the international specialty pharmaceutical company, and Invida Holdings Private Limited, a leader in the commercialisation of specialty biopharmaceutical and healthcare products throughout Asia Pacific, announce that their partnership has already led to the launch of two Sinclair IS dermatology products in seven Asia-Pacific markets.

30 Sep 2011

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.

26 Sep 2011

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Anacor Pharmaceuticals announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK '052, formerly AN3665), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.

7 Sep 2011

Perrigo's ANDA for Ketoconazole Foam, 2% receives final FDA approval to treat seborrheic dermatitis

Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.

31 Aug 2011

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Amgen today announced that it will present data from several Prolia (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011.

19 Aug 2011

Stress management can improve chronic skin conditions

As anyone with a chronic, inflammatory skin condition, such as psoriasis, rosacea or acne, knows, dealing with unpredictable flares can cause considerable stress and have a negative impact on a person's overall well-being.

4 Aug 2011

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine).

28 Jul 2011

EC approves YERVOY for treatment of previously-treated advanced melanoma

Bristol-Myers Squibb today announced that the European Commission has approved YERVOY for the treatment of adult patients with previously-treated advanced melanoma.

14 Jul 2011

New corticosteroid with cream-like base

Upsher-Smith Laboratories, Inc. announced the launch of Trianex 0.05% (Triamcinolone Acetonide Ointment), a prescription topical corticosteroid offering the feel of a cream with the strength of an ointment.

11 Jul 2011

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced receipt from Mallinckrodt Inc., a Covidien company (Covidien), of top-line results from a Phase 2 study conducted by Covidien, of twice-daily administration of PENNSAID Viscous Solution (topical diclofenac sodium viscous solution) 2% w/w, previously referred to as PENNSAID Gel.

30 Jun 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

Dermatitis News and Research

Latest Dermatitis News and Research

Provectus announces data from Phase 2 PV-10 metastatic melanoma study

Enrollment complete in Anacor's first of two tavaborole Phase 3 trials for onychomycosis

KYTHERA presents long-term results from ATX-101 Phase 2 study at ASDS 2011

Study evaluates availability of information about cosmetic ingredients for celiac patients

Thanksgiving Day tips for people with food allergies

Lifestyle factors and nutritional patterns reduce early causes of childhood allergy

UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs

Creabilis receives $20 million in Series B funding

Six sneaky triggers of allergies and asthma

Invida, Sinclair IS launch two dermatology products in seven Asia-Pacific markets

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Perrigo's ANDA for Ketoconazole Foam, 2% receives final FDA approval to treat seborrheic dermatitis

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Stress management can improve chronic skin conditions

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

EC approves YERVOY for treatment of previously-treated advanced melanoma

New corticosteroid with cream-like base

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Dermatitis News and Research

Latest Dermatitis News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in